Pharmacoeconomics of Helicobacter pylori: eradication versus maintenance therapy in controlling peptic ulcer disease

R M Klok, J R Brouwers, Maarten Postma*

*Corresponding author for this work

    Research output: Contribution to journalArticleAcademicpeer-review

    2 Citations (Scopus)


    We performed an electronic search in Medline and EMBASE for papers comparing Helicobacter pylori eradication and H(2)RA-maintenance therapy in peptic ulcer. Treatment to eradicate H. pylori in patients with a proven ulcer has a favorable cost-effectiveness compared with maintenance therapy, with benefits for the patient and society. In most studies, it was assumed that no more gastrointestinal drugs were needed after eradication. Additional research is needed to provide empirical evidence on gastrointestinal drug utilization after eradication of H. pylori. The development of a vaccine against H. pylori remains however the ultimate goal in the fight against peptic ulcer disease.

    Original languageEnglish
    Pages (from-to)19-24
    Number of pages6
    JournalExpert review of pharmacoeconomics & outcomes research
    Issue number1
    Publication statusPublished - Oct-2001

    Cite this